TheEdgeResearch
Home / Stocks / LSDI

Lucy Scientific Discovery Inc. (LSDI)

NASDAQ Healthcare Drug Manufacturers - Specialty & Generic
$0.51 ▼ -23.29%
Market Cap
$906,910
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Beta
0.71
52-Wk Range
0.44-12.8
CEO
Richard D. Nanula
Country
CA
Currency
USD

Lucy Scientific Discovery Inc. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Victoria, BC, CA. The stock last traded at $0.51, down 23.29% on the session, giving a market capitalisation of $906,910. On trailing twelve-month figures it carries a trailing P/E of -0.72, a net margin of -127532.0%. Its beta of 0.71 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-0.72
Price / Sales
128.68
Price / Book
1.40
EV / EBITDA
-0.18
Gross margin
36.2%
Operating margin
-82919.7%
Net margin
-127532.0%
Return on equity
Debt / equity
0.38
Current ratio
1.41
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Capital Market
Employees
2
IPO date
2023-02-09
Headquarters
Victoria, BC, CA
About Lucy Scientific Discovery Inc.

Lucy Scientific Discovery Inc. focuses on the entire lifecycle of psychedelic products, from their initial research and development to their production and subsequent market release. The company's offerings include fundamental biological raw materials, unprocessed extracts, a variety of psychotropic compounds, and critical active pharmaceutical ingredients (APIs). Established in 2017, this firm, formerly known as Hollyweed North Cannabis, Inc., is headquartered in Victoria, Canada.

Comparable companies

Lucy Scientific Discovery Inc. is most often compared with the following Healthcare names:

ACORAXDXCYTHHTGMQIMPLNEPTFNMTRQNVIVPAVMYCBD
More research on LSDI
LSDI technical analysis LSDI TheEdge Score Compare against peers
Open full interactive analysis & DCF →